Search Results - "Paugy, P"

Evaluation of the impact of information about treatment-related risks in patients receiving blood-derived or recombinant medications by Magli-Barioz, D., Ounnoughène, N., Paugy, P., Quarrè, M.-C., Vassilief, D., Lopez, I., Goudemand, J., Negrier, C., Assogba, U., Driss, F., A.-Dumont, M., Molho, P.

“…The aims of the study were to evaluate the impact of a written information about treatment related risks in patient receiving blood derived or recombinant…”
Get full text

FranceCoag: a 22-year prospective follow-up of the national French cohort of patients with inherited bleeding disorders by Doncarli, Alexandra, Demiguel, Virginie, Canu, Irina Guseva, Goulet, Véronique, Bayart, Sophie, Calvez, Thierry, Castet, Sabine, Dalibard, Vincent, Demay, Yohan, Frotscher, Birgit, Goudemand, Jenny, Lambert, Thierry, Milien, Vanessa, Oudot, Caroline, Sannié, Thomas, Chambost, Hervé

“…FranceCoag is an ongoing open prospective multicentre cohort project aimed at improving epidemiological knowledge about inherited bleeding disorders in France…”
Get full text

Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey by Poon, M‐C., D'Oiron, R., Von Depka, M., Khair, K., Négrier, C., Karafoulidou, A., Huth‐Kuehne, A., Morfini, M.

“…Background: Antibodies to glycoprotein (GP) IIb‐IIIa and/or HLA may render platelet transfusions ineffective to stop bleeding or to cover surgery in patients…”
Get full text

Interest of transjugular liver biopsy in adult patients with haemophilia or other congenital bleeding disorders infected with hepatitis C virus by Stieltjes, Natalie, Ounnoughene, Nadra, Sava, Emilie, Paugy, Patricia, Roussel‐Robert, Valérie, Rosenberg, Arielle R., Terris, Benoit, Salmon‐Céron, Dominique, Sogni, Philippe

“…Summary Liver histology is important for prognosis and treatment strategy in patients with hepatitis C. We report a 10‐year experience of transjugular liver…”
Get full text

Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia by Poon, M C, d'Oiron, R, Hann, I, Négrier, C, de Lumley, L, Thomas, A, Karafoulidou, A, Demers, C, Street, A, Huth-Kühne, A, Petrini, P, Fressinaud, E, Morfini, M, Tengborn, L, Marquès-Verdier, A, Musso, R, Devecioglu, O, Houston, D S, Lethagen, S, Van Geet, C, von Depka, M, Berger, C, Beurrier, P, Britton, H A, Gerrits, W, Guthner, C, Kuhle, S, Lorenzo, J J, Makris, P E, Nohe, N, Paugy, P, Pautard, B, Torchet, M F, Trillot, N, Vicariot, M, Wilde, J, Winter, M, Chambost, H, Ingerslev, J, Peters, M, Strauss, G

“…Recombinant factor VIIa (rFVIIa; NovoSeven, Novo Nordisk, Bagsvaerd, Denmark) appears effective and relatively safe for the treatment of bleeding and for…”
Get more information